Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--is now no longer listed as being in short supply in the U.S. and the FDA has told anyone distributing copies of the ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

PRESS RELEASE FROM THE MINISTRY OF HEALTH AND HUMAN SERVICES Cockburn Town, Turks and Caicos Islands, 2nd May 2025: In response to a U.S. Food and Drug Administration (FDA) alert relating to the ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...